DEA Proposes Extension of Telehealth Rules

The Drug Enforcement Administration (DEA) has proposed extending telemedicine prescribing flexibilities for controlled substances, amid pressure from Congress and healthcare advocates. The proposed rule aims to extend current flexibilities for one to two more years, allowing telehealth providers to prescribe controlled substances without requiring an in-person visit. Lawmakers have raised concerns about a draft rule that may limit telemedicine access and exclude certain medications, stressing the need for timely action to prevent patient care disruptions. The DEA's ongoing negotiations with the Office of Management and Budget (OMB) could affect the future of these rules, as stakeholders fear the proposed regulations may hinder telehealth's effectiveness. A third extension is anticipated to provide temporary relief for telemedicine services before a more permanent solution is established. Without this extension, many patients could lose access to critical telehealth services starting January 1, 2025.